We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Although it has no drugs on the market, KaloBios Pharmaceuticals has announced that it will limit price increases to the rate of inflation or Consumer Price Index, and will do so no more than once a year. Read More
Two lawmakers are mulling contempt proceedings against outgoing Valeant CEO J. Michael Pearson after he failed to provide a deposition on Friday as part of an investigation into drug pricing. Read More
A federal judge has dismissed a major portion of the lawsuits accusing Pfizer of failing to warn about possible birth defects associated with taking the antidepressant Zoloft during pregnancy. Read More
Five companies are throwing their support behind Sequenom’s efforts to have the U.S. Supreme Court reconsider the limits of patent eligibility. Read More
It took Pfizer and Allergan less than 48 hours to nix their plan to build one of the world’s largest drugmakers, placing the blame squarely on the U.S. Treasury Department. Read More
The largest drug merger of all time could be at risk of falling through after the U.S. Treasury Department late Monday issued a set of regulations that reduce the benefit of tax inversion deals. Read More